The global acne drugs market size was exhibited at USD 6.51 billion in 2022 and is projected to hit around USD 15.69 billion by 2032, growing at a CAGR of 9.2% during the forecast period 2023 to 2032.
Key Pointers:
- By type, inflammatory acne captured more than 59.0% of the market in 2022. Comedonal acne were ranked second-largest, among other types
- On the basis of therapeutic class, retinoids led the market in 2022, followed by antibiotics. This trend is likely to continue through 2032
- The treatment paradigm is shifting toward combination therapies and biologics. Combination products are gaining traction due to higher efficacy, convenient dosing, and fewer adverse effects
- Topical products dominated the treatment landscape, based on mode of administration. However, introduction of biologics is likely to result in the growth of the injectables segment
- U.S. dominated the major markets and is projected to maintain its lead through 2032, owing to rising disease incidence and ease of access to anti-acne products
- Allergan, Bayer, Galderma, Stiefel, and Valeant are some key players operating in this market. Valeant is projected to lead the market in 2032 due to higher adoption of Retin-A micro as well as anticipated launch of pipeline candidates.
Acne Drugs Market Report Scope
| Report Coverage |
Details |
| Market Size in 2023 |
USD 7.1 Billion |
| Market Size by 2032 |
USD 15.69 Billion |
| Growth Rate From 2023 to 2032 |
CAGR of 9.2% |
| Base Year |
2022 |
| Forecast Period |
2023 to 2032 |
| Segments Covered |
Type, Therapeutic Class, Mode of Administration |
| Market Analysis (Terms Used) |
Value (US$ Million/Billion) or (Volume/Units) |
| Regional Scope |
North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
| Key Companies Profiled |
Allergan Plc, AndroScience, Anterios, Aqua Pharmaceuticals, Bayer HealthCare, Cipher Pharmaceuticals Galderma S.A., GlaxoSmithKline Plc (Stiefel Laboratories, Inc.), Johnson & Johnson, Mayne Pharma Group Limited, Mylan N.V., Nestlé S.A. (Galderma S.A.), Oculus Innovative Sciences, Pfizer Inc. |
Several factors such as emergence of biologics, unhealthy lifestyle, and rising disease incidence are anticipated to drive the market.
Acne vulgaris is one of the most common dermatological disorders, affecting 9.4% people worldwide. Although the condition can affect people of all ages, it is most prevalent among teenagers. It has been found that the condition is prevalent in more than 85.0% people between the ages of 12 and 25. Acne can appear in forms ranging from comedones to cystic lesions, depending on its severity.
Retinoids and antibiotics remain the mainstays of acne treatment. Retinoids led the therapeutic classes in 2022, and it is expected to continue this trend through 2032. The therapeutic landscape is witnessing a shift toward combination treatment due to higher efficacy, convenient dosing, and fewer adverse effects.
By mode of administration, topical drugs currently dominate the market. Severe cases see the use of systemic medications such as oral antibiotics, hormonal agents, or other drugs. However, emergence of biologics (Gevokizumab and RA-18C3) will fuel the injectable route of administration. Biologics offer improved clinical advantage over conventional topical treatments since they target inflammatory mechanisms with disease modifying ability.
Discontinuation or termination of key pipeline candidates on account of unsuccessful clinical trials is a major restraint this market faces. Upon launch, Olumacostat glasaretil (Dermira; topical lipid synthesis inhibitor) was expected to be the first topical anti-acne drug with isotretinoin-like results without significant side effects. However, the drug failed to meet clinical endpoints, leading to discontinuation in March 2018. Similarly, SNA-001 (Sienna; silver nanoparticles solution) was deemed unsuccessful in two key trials wherein it was tested in conjunction with 810nm and 1064nm lasers in July 2018. Thesan withdrew TSN2898 from Phase II trials due to drug unavailability. Xenon discontinued development of XEN801 after the drug failed Phase II clinical trials.
Despite being one of the most common dermatological diseases in the world, innovation in acne treatment has been rather limited over the past decade. Drug companies are currently exploring novel treatment approaches including stearoyl CoA desaturase inhibition, melanocortin receptor antagonism, and anti-IL-1 monoclonal antibodies. Impending launch of late-stage pipeline products indicate a promising future for the global acne drugs market.
Some of the prominent players in the Acne Drugs Market include:
- Allergan Plc
- AndroScience
- Anterios
- Aqua Pharmaceuticals
- Bayer HealthCare
- Cipher Pharmaceuticals
- Galderma S.A.
- GlaxoSmithKline Plc (Stiefel Laboratories, Inc.)
- Johnson & Johnson
- Mayne Pharma Group Limited
- Mylan N.V.
- Nestlé S.A. (Galderma S.A.)
- Oculus Innovative Sciences
- Pfizer Inc.
- Reckitt Benckiser
- Skinvisible Pharmaceuticals
- Stiefel
- Sun Pharmaceutical Industries Limited
- Teva Pharmaceutical Industries Ltd.
- Valeant Pharmaceuticals International, Inc.
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Acne Drugs market.
By Type
- Comedonal
- Inflammatory
- Cystic
- Postsurgical/wound
By Therapeutic Class
- Retinoid
- Antibiotic
- Hormonal Agent
- Combination
- Others
By Mode of Administration
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa (MEA)
Request Customization
Get a Sample
Get a Sample
Request Customization